Eledon Pharmaceuticals: Strong Financials and Promising Clinical Developments Justify Buy ...
Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...